Table 2.

IDMC recommendations from first four meetings

First Meeting (25 February 2009):
∙	Requested details of adverse event reporting and listings of all individual events by patient identification
Second Meeting (18 June 2009):
∙	Requested information on children screened for the trial but not enrolled
∙	Requested the number and quantity of additional fluids (other than boluses) given to all children
∙	Asked the study teams to make extra effort to ensure that all children attend for neurological examination at 28 days
Third meeting (12 October 2009):
∙	Endorsed the review procedure for SAE proposed, and stressed the importance of blinded review by the ERC
∙	Accepted co-enrollment of children into other studies
∙	Noted planned sub-studies
Fourth meeting (26 January 2010, third interim analysis):
∙	Observed improvement in attendance for neurological follow up at 28 days
∙	Referred the request by a local IRB for representation on the IDMC to the TSC
∙	Requested more detailed information on all fluids received in each arm by time from randomization
∙	Agreed with the proposed plan of analysis